Drugs / Autologous Natural Killer Cell Therapy
Autologous Natural Killer Cell Therapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06044506 | Aug 2022 → Dec 2026 expected | hepatocellular carcinoma | Dr Cipto Mangunkusumo General Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Natural Killer Cell Therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06044506 ↗ |
| Modality | Cell therapy | “natural killer (NK) cell therapy” NCT06044506 ↗ |
| Route | Intravenous | “administered intravenously” NCT06044506 ↗ |